利法西明治疗质结肠炎:一个随机,双盲,安慰剂控制的试验
Sabine Becker1, Louise B Grode2, Ole K Bonderup1
1Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.
Inflammatory intestinal diseases
|February 6, 2024
概括
将rifaximin添加到budesonide可能有助于原性结肠炎患者更长时间保持缓解期. 这项研究表明,利法西明可能会降低复发率,尽管由于样本规模较小,需要进行更多研究.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
- 药理学 药理学是指药理学的学科.
背景情况:
- 质结肠炎 (CC) 是一种致残的疾病,通常需要长期的布索尼德治疗.
- 对于CC的治疗选择有限,需要探索新的治疗策略.
- 利法西明是一种吸收不良的抗生素,对肠道微生物群的组成有积极的影响.
研究的目的:
- 评估将利法西明添加到布德索尼德的疗效,以减少原性大肠炎患者的复发率.
- 评估组合治疗对维持CC患者临床缓解的影响.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的试验.
- 有活性CC的患者接受了开放标签的布德索尼德,然后随机分配到利法西明或安慰剂,如果缓解.
- 该研究比较了12周的随访期间里法西明和安慰剂组之间的复发率和缓解时间.
主要成果:
- 与安慰剂相比,rifaximin组显示出更长的缓解持续时间 (中位数为42天而不是18.5天) 和更低的复发率 (1.33比3.25每100人-天) 的趋势.
- 虽然这些发现并不具有统计学意义 (p=0.0996),但这些发现表明rifaximin的潜在益处.
- 一个小样本大小 (n=15) 是一个显著的限制.
结论:
- 将利法西明添加到布德索尼德可以为维持原性结肠炎患者的缓解提供潜在的益处.
- 需要进一步的大规模研究来证实这种联合治疗的疗效和安全性.
- 这项研究强调了对原性结肠炎更有效的治疗方法的需要.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drugs for Treatment of Constipation-Predominant IBS
169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334


